Afatinib (Gilotrif®) Management in Non-Small Cell Lung Cancer

The purpose of this PQI is to provide information on the management of common adverse events, follow-up with patients, and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions. In Lux-Lung 3, 43% maintained the 40 mg starting dose, 38% reduced to 30mg and 19% further reduced to 20 mg. Progression free survival remained consistent in patients with or without dose adjustments.